Talon Thanks...I remember and old expression ..."Leadership is like pornography, it is hard to describe, but you know it when you see it".
IS ACTC code for leadership? Can they answer the question..." Why is a company like BIIB (allowed to) still chase the AD Plaque illusion when we have limited resources (staff/pts/sites) to do such things?
I hope we see a plan, dates, schedules, commitments, resources and most of all some one or a group who will identify priorities, schedules, results along with activities of leading. I expect that academics bring a lot of knowledge and good thoughts on how to be supportive. I am looking for someone(Central control) to stick up their hand and declare they have the job and will take responsibility for the effective treatment of CNS diseases. Right now we have a herd of investors/Hedge funds/MM/micro/macro biotec/BP/3rd parties (like MJF), academics/FDA and various WW regulators w/o a plan. They are leaderless. In the U.S. it looks like BP/hedgies/MM/and FDA have a closed loop on who/what gets promoted/done.
Simply trusting that eventually a company like AVXL will produce results is where we are now. Biotec investing is an extremely risky act of faith, we all get that. Any assessment of the FDA pharma new device/pharma approvals process for AD (and other CNS) would declare it to be a complete failure for at least the past 40 years. Lets hope ACTC is truly a new beginning and not just building on what is now in place. IMO, Gottlieb has to do this.
Thx
